Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News

Andrew Brenner, M.D., Ph.D., one of Plus Therapeutics’ Principal Investigators for the RESPECT-GBM clinical trial, recently appeared on KABB News with Melissa Vega to discuss the ongoing battle against glioblastoma (GBM)—one of the most aggressive and treatment-resistant forms of brain cancer.

In the interview, Dr. Brenner shared insights into our investigational therapy, REYOBIQ™, a novel targeted radiation therapy designed to improve precision and efficacy in the treatment of recurrent GBM. Delivered directly into the tumor cavity, REYOBIQ™ aims to concentrate therapeutic radiation exactly where it’s needed—maximizing impact while minimizing harm to surrounding healthy brain tissue.

Watch the full interview here: KABB News Interview

Dr. Brenner and his team at the Mays Cancer Center at UT Health San Antonio are playing a vital role in advancing the ReSPECT-GBM Phase 2 trial, which is currently enrolling patients. Their commitment to cutting-edge research and compassionate care is helping move the field of neuro-oncology forward.

Now Enrolling: ReSPECT-GBM Clinical Trial

The RESPECT-GBM trial is investigating REYOBIQ™ for patients with recurrent glioblastoma. If you or someone you know may be eligible to participate, we encourage you to reach out.

Contact us: respect@plustherapeutics.com
Learn more: respect-trials.com/gbm

#Glioblastoma #GBM #BrainCancer #BrainTumor #REYOBIQ #RadiationTherapy #Radiotherapeutics #RESPECTGBM #ClinicalTrials #Oncology #CancerResearch #BrainTumorStrong #NeuroOncology #PSTV #PlusTherapeutics #UTHealth #MaysCancerCenter #KABBNews #SinclairBroadcastGroup